Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 303

1.

PPM1D controls nucleolar formation by up-regulating phosphorylation of nucleophosmin.

Kozakai Y, Kamada R, Furuta J, Kiyota Y, Chuman Y, Sakaguchi K.

Sci Rep. 2016 Sep 13;6:33272. doi: 10.1038/srep33272.

2.

Suppression of Vimentin Phosphorylation by the Avian Reovirus p17 through Inhibition of CDK1 and Plk1 Impacting the G2/M Phase of the Cell Cycle.

Chiu HC, Huang WR, Liao TL, Wu HY, Munir M, Shih WL, Liu HJ.

PLoS One. 2016 Sep 7;11(9):e0162356. doi: 10.1371/journal.pone.0162356. eCollection 2016.

3.

Molecular and Cellular Effects of Hydrogen Peroxide on Human Lung Cancer Cells: Potential Therapeutic Implications.

Vilema-Enríquez G, Arroyo A, Grijalva M, Amador-Zafra RI, Camacho J.

Oxid Med Cell Longev. 2016;2016:1908164. doi: 10.1155/2016/1908164. Epub 2016 Jun 8. Review.

4.

Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy.

Manic G, Obrist F, Sistigu A, Vitale I.

Mol Cell Oncol. 2015 Feb 23;2(4):e1012976. doi: 10.1080/23723556.2015.1012976. eCollection 2015 Oct-Dec. Review.

5.

14-3-3γ Prevents Centrosome Amplification and Neoplastic Progression.

Mukhopadhyay A, Sehgal L, Bose A, Gulvady A, Senapati P, Thorat R, Basu S, Bhatt K, Hosing AS, Balyan R, Borde L, Kundu TK, Dalal SN.

Sci Rep. 2016 Jun 2;6:26580. doi: 10.1038/srep26580.

6.

Erratum to: Controlling the response to DNA damage by the APC/C-Cdh1.

de Boer HR, Llobet SG, van Vugt MA.

Cell Mol Life Sci. 2016 Aug;73(15):2985-2998. No abstract available.

7.

Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis.

Al Nakouzi N, Wang CK, Beraldi E, Jager W, Ettinger S, Fazli L, Nappi L, Bishop J, Zhang F, Chauchereau A, Loriot Y, Gleave M.

EMBO Mol Med. 2016 Jul 1;8(7):761-78. doi: 10.15252/emmm.201506059.

8.

A Genome-wide CRISPR Screen Identifies CDC25A as a Determinant of Sensitivity to ATR Inhibitors.

Ruiz S, Mayor-Ruiz C, Lafarga V, Murga M, Vega-Sendino M, Ortega S, Fernandez-Capetillo O.

Mol Cell. 2016 Apr 21;62(2):307-13. doi: 10.1016/j.molcel.2016.03.006. Epub 2016 Apr 7.

PMID:
27067599
9.

Phosphatases and kinases regulating CDC25 activity in the cell cycle: clinical implications of CDC25 overexpression and potential treatment strategies.

Sur S, Agrawal DK.

Mol Cell Biochem. 2016 May;416(1-2):33-46. doi: 10.1007/s11010-016-2693-2. Epub 2016 Apr 2. Review.

PMID:
27038604
10.

New origin firing is inhibited by APC/CCdh1 activation in S-phase after severe replication stress.

Ercilla A, Llopis A, Feu S, Aranda S, Ernfors P, Freire R, Agell N.

Nucleic Acids Res. 2016 Jun 2;44(10):4745-62. doi: 10.1093/nar/gkw132. Epub 2016 Mar 2.

11.

High Mobility Group A2 protects cancer cells against telomere dysfunction.

Natarajan S, Begum F, Gim J, Wark L, Henderson D, Davie JR, Hombach-Klonisch S, Klonisch T.

Oncotarget. 2016 Mar 15;7(11):12761-82. doi: 10.18632/oncotarget.6938.

12.

The ascidian natural product eusynstyelamide B is a novel topoisomerase II poison that induces DNA damage and growth arrest in prostate and breast cancer cells.

Liberio MS, Sadowski MC, Davis RA, Rockstroh A, Vasireddy R, Lehman ML, Nelson CC.

Oncotarget. 2015 Dec 22;6(41):43944-63. doi: 10.18632/oncotarget.6267.

13.

A Novel Aspect of Tumorigenesis-BMI1 Functions in Regulating DNA Damage Response.

Lin X, Ojo D, Wei F, Wong N, Gu Y, Tang D.

Biomolecules. 2015 Dec 1;5(4):3396-415. doi: 10.3390/biom5043396. Review.

14.

Salternamide A Suppresses Hypoxia-Induced Accumulation of HIF-1α and Induces Apoptosis in Human Colorectal Cancer Cells.

Bach DH, Kim SH, Hong JY, Park HJ, Oh DC, Lee SK.

Mar Drugs. 2015 Nov 19;13(11):6962-76. doi: 10.3390/md13116962.

15.

A haploid genetic screen identifies the G1/S regulatory machinery as a determinant of Wee1 inhibitor sensitivity.

Heijink AM, Blomen VA, Bisteau X, Degener F, Matsushita FY, Kaldis P, Foijer F, van Vugt MA.

Proc Natl Acad Sci U S A. 2015 Dec 8;112(49):15160-5. doi: 10.1073/pnas.1505283112. Epub 2015 Nov 23.

16.

In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia.

Iacobucci I, Di Rorà AG, Falzacappa MV, Agostinelli C, Derenzini E, Ferrari A, Papayannidis C, Lonetti A, Righi S, Imbrogno E, Pomella S, Venturi C, Guadagnuolo V, Cattina F, Ottaviani E, Abbenante MC, Vitale A, Elia L, Russo D, Zinzani PL, Pileri S, Pelicci PG, Martinelli G.

J Hematol Oncol. 2015 Nov 5;8:125. doi: 10.1186/s13045-015-0206-5.

17.

Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.

Qi W, Zhang W, Edwards H, Chu R, Madlambayan GJ, Taub JW, Wang Z, Wang Y, Li C, Lin H, Ge Y.

Cancer Biol Ther. 2015;16(12):1784-93. doi: 10.1080/15384047.2015.1095406.

PMID:
26529495
18.

MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways.

Estrada-Bernal A, Chatterjee M, Haque SJ, Yang L, Morgan MA, Kotian S, Morrell D, Chakravarti A, Williams TM.

Cell Cycle. 2015;14(23):3713-24. doi: 10.1080/15384101.2015.1104437.

PMID:
26505547
19.

Label-free DNA imaging in vivo with stimulated Raman scattering microscopy.

Lu FK, Basu S, Igras V, Hoang MP, Ji M, Fu D, Holtom GR, Neel VA, Freudiger CW, Fisher DE, Xie XS.

Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):11624-9. doi: 10.1073/pnas.1515121112. Epub 2015 Aug 31. Erratum in: Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):E5902.

20.

Small molecule inhibitors of Late SV40 Factor (LSF) abrogate hepatocellular carcinoma (HCC): Evaluation using an endogenous HCC model.

Rajasekaran D, Siddiq A, Willoughby JL, Biagi JM, Christadore LM, Yunes SA, Gredler R, Jariwala N, Robertson CL, Akiel MA, Shen XN, Subler MA, Windle JJ, Schaus SE, Fisher PB, Hansen U, Sarkar D.

Oncotarget. 2015 Sep 22;6(28):26266-77. doi: 10.18632/oncotarget.4656.

Items per page

Supplemental Content

Write to the Help Desk